GSK 4529 is primarily investigated for its antiviral properties, with a focus on the treatment of hepatitis C virus (HCV) infections. It functions as an NS5A inhibitor, disrupting viral replication by targeting the NS5A protein, which is essential for the HCV life cycle. Due to its high potency and ability to suppress viral load at low concentrations, GSK 4529 has been studied as part of combination therapies with other antiviral agents such as NS3/4A protease inhibitors or polymerase inhibitors. These combinations aim to improve cure rates, reduce treatment duration, and minimize the risk of drug resistance. Its development supports the broader goal of creating all-oral, interferon-free regimens for chronic HCV patients, offering improved tolerability and higher efficacy across multiple HCV genotypes.